

Clinical Study Results

This summary reports the results of only one study. Researchers must look at the results of many types of studies to understand if a study medication works, how it works, and if it is safe to prescribe to patients. The results of this study might be different than the results of other studies that the researchers review.

Sponsor: Pfizer Inc.

Medicine(s) PF-07295324 and PF-07259955

Studied:

Protocol Number: C4711001

Dates of Study: 09 February 2022 to 12 August 2022

Title of this Study: A Study to Investigate the Safety, and

Tolerability, of Topically Administered PF-

07295324 and PF-07259955, in Healthy Adults

[A Phase 1, Randomized, Double-Blind, Sponsor-Open, Vehicle-Controlled, First-in-Human, Multiple-Dose Study, to Investigate the Safety, Tolerability, and Pharmacokinetics, of Topically Administered PF-07295324 and PF-07259955, in Healthy Adult Participants]

Date(s) of this 12 June 2023 Report:

Thank You –





If you participated in this study, Pfizer, the Sponsor, would like to thank you for your participation.

This summary will describe the study results. If you have any questions about the study or the results, please contact the doctor or staff at your study site.



Why was this study done?

What is Atopic dermatitis?

Atopic dermatitis (or "AD"), which is also sometimes called atopic eczema, is a common skin disorder that causes patches of flaky, red, and very itchy skin. AD occurs in 15%-30% of children and 10% of adults in the United States. Some of the current medicines available for AD can only be used for short time periods or can cause other health problems. Researchers are looking for new treatments for AD that can be taken for long periods of time.

While researchers think that many things cause AD, it is made worse by the body's immune system (the body's defense against infection) causing redness and swelling (inflammation). Cells in the immune system cause inflammation by making special proteins called "cytokines". Researchers think that medicines that lower the effect of cytokines that could help treat patients with AD.

What are PF-07295324 and PF-07259955?

PF-07295324 and PF-07259955 are experimental drugs that have not been approved for sale yet. PF-07295324 and PF-07259955 block the activity of proteins called "Janus kinases", which act like an on/off switch in cells. By turning off this switch, the cells are less responsive to cytokines that are believed to make AD worse. PF-07295324 and PF-07259955 are applied to skin as an ointment or a cream, respectively. The formulations used are PF-07295324 (0.12% weight per weight [w/w]) and PF-07259955 (2% w/w), on approximately 20% body surface area (BSA) in healthy adult participants.



What was the purpose of this study?

The purpose of this study was to determine the safety and tolerability of PF-07295324 (0.12% w/w) ointment and PF-07259955 (2% w/w) cream when applied individually to healthy adult participants.

Researchers wanted to know:

 What medical problems did participants have during the study?

What happened during the study?

How was the study done?

Researchers tested on a group of healthy participants to learn if application of PF-07295324 as an ointment and PF-07259955 as a cream, individually to the skin caused any medical problems.

Participants were divided in to 4 cohorts (groups).


- 4 participants in Cohort 1 received PF-07295324 twice daily
- 2 participants received the PF-07295324 vehicle (vehicle is the medium in which the medicine is dissolved to make it applicable) twice daily
- 4 participants in Cohort 2 received PF-07259955 twice daily
- 2 participants received PF-07259955 vehicle twice daily
- 4 participants in Cohort 3 received PF-07295324 twice daily
- 2 participants received PF-07295324 vehicle twice daily



- 4 participants in Cohort 4 received PF-07295324 once daily
- 2 participants received PF-07295324 vehicle once daily

The study design is shown in Figure 1

Figure 1: How was the study done?



- a. PF-07295324 (0.12%)/vehicle cintment in Cohort 1 or PF-07259955 (2%)/vehicle cream in Cohort 2, was topically applied every 12 hours from Day 1 to Day 9 and once on Day 10
- b. Cohort 3 was enrolled to repeat the PF-07295324 dose studied in Cohort 1
- c. Cohort 4 PF-07295324 (0.12%) /vehicle ointment applied once daily

Researchers checked the participants' health during the study and asked them how they were feeling.

Researchers then compared the results of participants treated with PF-07295324 to those treated with its vehicle, and the results of participants treated with PF-07259955 to those treated with its vehicle.

The participants and researchers did not know who received PF-07295324, who received PF-07259955, and who received vehicles. This is known as a "blinded" study. Participants were assigned to each group by chance alone.



Where did this study take place?

The Sponsor ran this study at 1 location in the United States.

When did this study take place?

It began 09 February 2022 and ended 12 August 2022.

Who participated in this study?

The study included healthy participants who met the inclusion/exclusion criteria such as age, weight etc.

- A total of 20 men participated
- A total 4 women participated
- All participants were between the ages of 53 and 58 years.

Of the 24 participants who started the study 1 participant did not finish the study because of non-compliance with the study drug.

No participants left before the study was over by their choice or because a doctor decided it was best for a participant to stop being in the study.

How long did the study last?

Study participants were treated for 10 days. The duration of participation from screening to follow-up was approximately 10 weeks. The entire study took 6 months to complete.

When the study ended in August 2022, the Sponsor began reviewing the information collected. The Sponsor then created a report of the results. This is a summary of that report.



What were the results of the study?

When PF-07295324 ointment was applied to the participants' skin twice daily, skin related medical problems in the application site were reported in moderate to high frequency. However, when the same drug was applied once daily in Cohort 4 skin related medical problems in the application site were much less frequent and PF-07295324 was generally safe and well tolerated. PF-07259955 cream applied twice daily was generally safe and well tolerated.

What medical problems did participants have during the study?

The researchers recorded any medical problems the participants had during the study. Participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). Or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. Sometimes the cause of a medical problem is unknown. By comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant.

13 out of 24 (54.16%) participants in this study had at least 1 medical problem. No participants left the study because of medical problems. All medical problems reported by participants are described below.



Note: The medical problems reported in each cohort are shown as Cohort A (patients who were treated with the medicine) and Cohort B (patients who were treated with the vehicle)

Below are instructions on how to read Table 1

Instructions for Understanding Table 1

- The 1st column of Table 1 lists medical problems that were reported during the study. All medical problems reported by the participants are listed.
- The 2nd column tells how many of the 4 participants who received PF-07295324 ointment twice daily (Cohort 1A) reported each medical problem.
- The **3rd** column tells how many of the 2 participants who received the PF-07295324 vehicle twice daily (Cohort 1B) reported each medical problem.
- The 4th column tells how many of the 4 participants who received PF- 07259955 cream twice daily (Cohort 2A) reported each medical problem.
- The 5th column tells how many of the 2 participants who received PF-07259955 vehicle twice daily (Cohort 2B) reported each medical problem.
- The 6th column tells how many of the 4 participants who received PF-07295324 ointment twice daily (Cohort 3A) reported each medical problem.



- The **7th** column tells how many of the 2 participants who received the PF-07295324 vehicle twice daily (Cohort 3B) reported each medical problem.
- The 8th column tells how many of the 4 participants who received PF-07295324 ointment once daily (Cohort 4A) reported each medical problem.
- The 9th column tells how many of the 2 participants who received the PF-07295324 vehicle once daily (Cohort 4B)reported each medical problem.
- Using these instructions, you can see that 0 out of the 4 participants who received PF-07295324 ointment twice daily reported application site dryness. A total of 0 out of the 2 participants who received PF-07295324 vehicle twice daily reported application site dryness.

Table 1. Medical problems reported by study participants Cohort 1 Cohort 2 Cohort 3 Cohort 4 Medical **Problem** 1 A 1 B 2 A 2 B 3 A 3 B 4 A 4 B Participants | Participants | Participants | Participants | Participants | Participants | **Participants** Participants Application site 0 out of 4 0 out of 2 0 out of 4 0 out of 2 0 out of 4 0 out of 2 1 out of 4 0 out of 2 participants participants participants participants participants participants participants participants dryness 0 out of 2 Application site 3 out of 4 0 out of 2 0 out of 4 0 out of 2 2 out of 4 1 out of 2 0 out of 4 redness (erythema) participants participants participants participants participants participants participants participants Application site 3 out of 4 0 out of 2 1 out of 4 0 out of 2 0 out of 4 0 out of 2 0 out of 4 0 out of 2 irritation participants participants participants participants participants participants participants participants





Table 1. Medical problems reported by study participants								
Medical Problem	Cohort 1		Cohort 2		Cohort 3		Cohort 4	
	1 A	1 B	2 A	2 B	3 A	3 B	4 A	4 B
	4	2	4	2	4	2	4	2
Application site pain	Participants 1 out of 4 participants	Participants 1 out of 2 participants	Participants 0 out of 4 participants	Participants 0 out of 2 participants	Participants 1 out of 4 participants	Participants 1 out of 2 participants	Participants 0 out of 4 participants	Participants 0 out of 2 participants
Application site bumps (papules)	1 out of 4 participants	0 out of 2 participants	1 out of 4 participants	0 out of 2 participants	2 out of 4 participants	0 out of 2 participants	1 out of 4 participants	0 out of 2 participants
Application site itching	3 out of 4 participants	1 out of 2 participants	0 out of 4 participants	0 out of 2 participants	3 out of 4 participants	1 out of 2 participants	0 out of 4 participants	0 out of 2 participants
Tiredness (fatigue)	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	1 out of 2 participants	0 out of 4 participants	0 out of 2 participants
Blood vessel tear (contusion)	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	1 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants
Scratch	1 out of 4 participants	1 out of 2 participants	0 out of 4 participants	0 out of 2 participants	2 out of 4 participants	1 out of 2 participants	1 out of 4 participants	0 out of 2 participants
Skin damage (abrasion)	1 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	1 out of 2 participants	0 out of 4 participants	0 out of 2 participants
Blood potassium increased	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	1 out of 2 participants	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants
Liver function test increased	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	1 out of 4 participants	0 out of 2 participants
Headache	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	1 out of 2 participants	0 out of 4 participants	0 out of 2 participants
Dry skin	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	1 out of 4 participants	0 out of 2 participants
Skin rash (intertrigo)	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	1 out of 2 participants	0 out of 4 participants	0 out of 2 participants
Skin bumps (Pseudofolliculitis)	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	1 out of 2 participants	0 out of 4 participants	0 out of 2 participants
Skin color loss (Hypopigmentation)	0 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants	1 out of 4 participants	0 out of 2 participants	0 out of 4 participants	0 out of 2 participants

Did study participants have any serious medical problems?





A medical problem is considered "serious" when it is life-threatening, needs hospital care, or causes lasting problems.

No participants had serious medical problems.





Where can I learn more about this study?

If you have questions about the results of your study, please speak with the doctor or staff at your study site.

For more details on your study protocol, please visit:

.

www.pfizer.com/research/ Use the protocol number

research_clinical_trials/trial_results C4711001

The full scientific report of this study is available online at:

www.clinicaltrials.gov Use the study identifier

NCT05206604

Please remember that researchers look at the results of many studies to find out which medicines can work and are safe for patients.

Again, if you participated in this study, thank you for volunteering.

We do research to try to find the best ways to help patients, and you helped us to do that!